SS-31: Uses, Benefits & Research

What is SS-31?

SS-31, known generically as elamipretide (also Bendavia, MTP-131), is a synthetic tetrapeptide (D-Arg-2-methyl-2',6'-dimethyltyrosine-Lys-Phe-NH2) with a molecular weight of 639.8 Da, designed to selectively target and restore mitochondrial function. Developed by Stealth BioTherapeutics (now acquired by Kirin), it is the most clinically advanced mitochondria-targeted peptide therapeutic.

SS-31 has an approximately 15-30 minute half-life via subcutaneous injection with about 70% bioavailability. It is currently investigational — not FDA-approved — but has received FDA Breakthrough Therapy designation for heart failure with preserved ejection fraction (HFpEF) in 2019 and Fast Track designation for primary mitochondrial disease. Two Phase 3 trials are actively recruiting with readouts expected in 2026-2027.

The compound is not available for compounding or general clinical use outside of clinical trials and expanded access programs. Composition of matter patents extend through 2032-2035, with method of use patents through 2036-2038.

Mechanism of Action

SS-31 works by targeting the mitochondria — specifically by binding to cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane:

Mechanistic Cascade

1. Cell penetration: SS-31 crosses cell membranes without a carrier and concentrates 1,000-5,000x in mitochondria
2. Cardiolipin binding: Selectively binds to cardiolipin on the inner mitochondrial membrane
3. Cardiolipin protection: Prevents cardiolipin peroxidation by reactive oxygen species
4. Cristae stabilization: Maintains normal mitochondrial cristae architecture
5. Supercomplex stabilization: Stabilizes electron transport chain supercomplexes (Complex I-III-IV assemblies)
6. Improved electron flow: Reduces electron leak and improves coupling of oxidative phosphorylation
7. Reduced ROS: Decreases superoxide production by 40-60%
8. Increased ATP: Net result is restored ATP production capacity

Molecular Targets

| Target | Evidence | Effect | |---|---|---| | Cardiolipin | Direct binding demonstrated | Stabilizes inner membrane; protects cristae | | ETC Complexes I-IV | Inferred from functional data | Improves efficiency; reduces electron leak | | ROS production | Direct measurement | 40-60% reduction in superoxide | | Mitochondrial membrane potential | Direct measurement | Restores membrane potential in damaged mitochondria |

This mechanism is particularly relevant in conditions where mitochondrial dysfunction drives disease pathology — heart failure, primary mitochondrial diseases, muscular dystrophies, and age-related cellular decline.

Clinical Evidence

Landmark Trials

| Trial | Phase | N | Population | Key Result | |---|---|---|---|---| | EMBRACE-HF | II | 67 | HFpEF | +42m 6MWD vs +10m placebo (PMID: 34289123) | | PROHIBIT | II | 185 | HFrEF | Well tolerated; improved mitochondrial markers | | MMPOWER-3 | II/III | 218 | Primary mitochondrial myopathy | Mixed primary endpoint; genotype-specific benefit (PMID: 37268435) | | TAZPOWER | II | 12 | Barth syndrome | 168-week safety/efficacy maintained (PMID: 38602181) | | SPIRE-1 | II | 250 | HFpEF | +1.8 vs +0.7 mL/kg/min peak VO2 | | DMD study | II | ~50 | Duchenne MD | Modest functional improvement |

Evidence Base

• Phase 2 trials completed: 8+
• Phase 3 trials active: 2 (SPRING-HF, n=600; mitochondrial disease, n=400)
• Total subjects exposed: 800-1,000
• Placebo-controlled RCTs: 6+

Key Limitation

While the mechanistic data is robust and consistent, some trials have shown mixed results on primary endpoints. The biomarker-to-clinical-outcomes gap — clear mitochondrial function improvement but variable functional endpoints — is the central question that Phase 3 trials must resolve.

Active Trials (as of March 2026)

| Trial | Phase | Status | N | Focus | |---|---|---|---|---| | SPRING-HF (NCT05065528) | III | Recruiting | 600 | HFpEF | | NCT05432142 | III | Recruiting | 400 | Primary mitochondrial disease |

Drug Interactions & Contraindications

SS-31 has a favorable drug interaction profile:

• Not metabolized by CYP450 — peptide cleared by proteolysis, minimizing hepatic drug interactions
• No known interactions from clinical trial data — can be combined with standard heart failure medications (ACEi, ARBs, beta-blockers, diuretics)
• Statins: No interaction expected based on clean co-administration data in trials
• Antioxidants: Theoretical additive/synergistic effect — no human interaction data

No formal contraindications have been identified in clinical trials. Pregnancy is avoided as the compound has not been studied in pregnant women.

Safety & Side Effects

SS-31 has demonstrated an excellent tolerability profile across all Phase 2 trials, with adverse event rates very close to placebo:

| Adverse Event | SS-31 | Placebo | Difference | |---|---|---|---| | Injection site reactions | 8-12% | 5-8% | Minimal | | Headache | 10-15% | 8-12% | Minimal | | Nausea | 6-10% | 5-8% | Minimal | | Dizziness | 5-8% | 4-6% | Minimal |

Key safety findings:

• No serious adverse events attributed to SS-31 in any Phase 2 trial
• Cardiac SAEs in heart failure populations occurred at rates consistent with underlying disease, not drug effect
• No treatment discontinuations exceeding placebo
• No effect on vital signs or ECG parameters
• 168-week open-label extension in Barth syndrome showed maintained safety (PMID: 38602181)

Long-term safety data beyond 168 weeks (Barth syndrome) and 1 year (other indications) is still accumulating.

Honest Bottom Line

SS-31 (elamipretide) represents one of the most scientifically rigorous approaches to mitochondrial dysfunction, with a well-characterized mechanism targeting cardiolipin on the inner mitochondrial membrane. Phase 2 data shows meaningful gains in exercise capacity for heart failure patients (42-meter improvement in 6-minute walk distance), and it has earned FDA Breakthrough Therapy designation for HFpEF.

However, evidence remains limited to Phase 2 trials with some mixed primary endpoint results. The Phase 3 readouts expected in 2026-2027 will be decisive for determining whether the clear mechanistic benefits translate to clinically meaningful functional outcomes. The safety profile appears favorable — adverse event rates are close to placebo — but the compound is not available outside clinical trials or expanded access programs. For patients interested in mitochondrial-targeted therapies, SS-31 is the most advanced candidate but remains investigational.